Press Releases

20.11.2020
DGAP-Media

Aladdin Healthcare Technologies announces update of its financial calendar 2020

BERLIN/LONDON November 20, 2020 - Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, announces an update to its financial calendar for the 2020 financial year.

Due to the ongoing coronavirus pandemic, which has resulted in a significant increase of the amount of work and an internal reorganization of the accounting staff, Aladdin has decided to postpone the publication of the Company´s financial statements for the financial year ended on December 31, 2019 and of the 2020 Annual General Meeting (AGM).

The audit of the Group´s financial statements is expected to be completed in the first half of December 2020 by the auditing company Warth & Klein Grant Thornton AG. Thereafter, Aladdin will immediately publish its annual report for the 2019 financial year. Furthermore, the invitation for the 2020 Annual General Meeting is expected to be published in the course of December, with the Meeting being held in January 2021. The update of the financial calendar will be communicated by Aladdin on the Company’s website and available for viewing at the Investor Relations section of the Company´s website.

Aladdin assures that it will use its best endeavours to ensure that the audit of the 2019 annual report will be completed as soon as possible. The Company will publish an ad-hoc release in the next weeks outlining any material numbers and announcing the time of publication as soon as an exact date is made clear by the auditing company.

About Aladdin Healthcare Technologies SE

Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information
Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: info@aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone +49 89 1250 90330
Email: sh@crossalliance.de
www.crossalliance.de